| 1.32 0.06 (4.76%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.88 | 1-year : | 2.25 |
| Resists | First : | 1.61 | Second : | 1.92 |
| Pivot price | 1.33  |
|||
| Supports | First : | 1.11 | Second : | 0.92 |
| MAs | MA(5) : | 1.25  |
MA(20) : | 1.42 |
| MA(100) : | 1.32 |
MA(250) : | 1.14 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.9 |
D(3) : | 13.2 |
| RSI | RSI(14): 45.7 |
|||
| 52-week | High : | 2.11 | Low : | 0.64 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CLSD ] has closed above bottom band by 47.5%. Bollinger Bands are 6.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.39 - 1.4 | 1.4 - 1.4 |
| Low: | 1.23 - 1.23 | 1.23 - 1.24 |
| Close: | 1.31 - 1.32 | 1.32 - 1.33 |
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Wed, 17 Apr 2024
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Mon, 15 Apr 2024
Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significant Drop in Short Interest - MarketBeat
Thu, 14 Mar 2024
Should You Add Clearside Biomedical Inc (CLSD) Stock to Your Portfolio Thursday? - InvestorsObserver
Wed, 13 Mar 2024
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript - Yahoo Finance
Wed, 13 Mar 2024
Earnings call: Clearside Biomedical reports on clinical trials and collaborations - Investing.com
Tue, 12 Mar 2024
Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 75 (M) |
| Held by Insiders | 6.925e+007 (%) |
| Held by Institutions | 7.1 (%) |
| Shares Short | 275 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.478e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -46 % |
| Return on Assets (ttm) | -36.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 353.09 |
| Sales Per Share | 3.53219e+006 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.31 |
| Dividend | 0 |
| Forward Dividend | 224270 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|